
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies is a regenerative and aesthetic medicine company with a strong focus on 3D bioprinting of tissues and organs. Despite challenges in the broader capital environment, the company remains dedicated to advancing its rhCollagen and BioInk programs, and currently has a promising partnership and revenue model with a diversified source of income streams. While the recently announced registered direct offering may result in near-term dilution risk, the company's long-term potential and innovative technology make it a compelling investment opportunity.
Bears say
CollPlant Biotechnologies is facing several fundamental risks, including clinical and regulatory challenges, partnership uncertainties, financial concerns, commercial obstacles, legal and intellectual property uncertainties, and the potential for loss of market share. Additionally, the company's revenues are currently low, and it has announced a reduction initiative which may indicate cost-cutting measures in response to financial strain. As of September 30, 2025, the company had a minimal amount of cash and cash equivalents, indicating potential liquidity concerns.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares